Milestone Pharma gains on FDA approval of nasal spray for patients with heart condition

Milestone Pharmaceuticals

15/12/2025 13:33

** Shares of Milestone Pharmaceuticals MIST.O surge 34.02% to $3.23 premarket

** U.S. Food and Drug Administration on Friday approved Milestone's first commercial product, Cardamyst, a nasal spray for adults with a heart condition

** The spray is designed to rapidly resolve episodes of paroxysmal supraventricular tachycardia - a type of irregular heartbeat - and restore sinus rhythm

** The spray is expected to be available in retail pharmacies in Q1 2026

** Up to last close, stock up 2% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com))